- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
- Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
More ▼
Key statistics
On Thursday, Cabaletta Bio Inc (CABA:NSQ) closed at 11.21, 24.28% above the 52 week low of 9.02 set on May 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.89 |
---|---|
High | 11.89 |
Low | 10.82 |
Bid | 10.72 |
Offer | 12.00 |
Previous close | 11.21 |
Average volume | 831.65k |
---|---|
Shares outstanding | 48.28m |
Free float | 45.05m |
P/E (TTM) | -- |
Market cap | 541.18m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼